Skip to content
10-Q

Quarterly Report

Actinium Pharmaceuticals, Inc. ATNM

0001213900-24-098534

← back to feed
Filed
Nov 14, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 14, 2024 31.2M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $78.66M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $76.68M
Current Liabilities Q3 2024 · Sep 30, 2024 $7.76M
Current Liabilities Q3 2024 · Dec 31, 2023 $8.49M
Total Liabilities Q3 2024 · Sep 30, 2024 $43.91M
Total Liabilities Q3 2024 · Dec 31, 2023 $45.07M
Current Assets Q3 2024 · Sep 30, 2024 $79.52M
Current Assets Q3 2024 · Dec 31, 2023 $78.26M
Total Assets Q3 2024 · Sep 30, 2024 $82.11M
Total Assets Q3 2024 · Dec 31, 2023 $81.45M
Shares Diluted Q3 2024 · Sep 30, 2023 27.06M sh
Shares Diluted Q3 2024 · Sep 30, 2023 26.33M sh
Capex Q3 2024 · Sep 30, 2023 $153K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$39.85M
Stockholders Equity Q3 2024 · Sep 30, 2023 $43.58M
Stockholders Equity Q3 2024 · Jun 30, 2023 $53.08M
Stockholders Equity Q3 2024 · Mar 31, 2023 $57.21M
Stockholders Equity Q3 2024 · Dec 31, 2022 $66.48M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.49
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.50
Eps Basic Q3 2024 · Sep 30, 2023 −$0.49
Eps Basic Q3 2024 · Sep 30, 2023 −$1.50
Sga Expense Q3 2024 · Sep 30, 2023 $2.73M
Sga Expense Q3 2024 · Sep 30, 2023 $11.03M
Rd Expense Q3 2024 · Sep 30, 2023 $11.62M
Rd Expense Q3 2024 · Sep 30, 2023 $30.55M
Net Income Q3 2024 · Sep 30, 2023 −$13.28M
Net Income Q3 2024 · Sep 30, 2023 −$39.49M
Net Income Q3 2024 · Jun 30, 2023 −$15.18M
Net Income Q3 2024 · Mar 31, 2023 −$11.04M
Operating Income Q3 2024 · Sep 30, 2023 −$14.35M
Operating Income Q3 2024 · Sep 30, 2023 −$41.58M